US Bancorp DE Reduces Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

US Bancorp DE reduced its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 33.4% during the 4th quarter, Holdings Channel reports. The fund owned 5,355 shares of the company’s stock after selling 2,688 shares during the period. US Bancorp DE’s holdings in Syndax Pharmaceuticals were worth $71,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in SNDX. R Squared Ltd acquired a new position in Syndax Pharmaceuticals in the 4th quarter valued at about $26,000. Quantbot Technologies LP purchased a new stake in shares of Syndax Pharmaceuticals during the third quarter worth about $49,000. KBC Group NV raised its position in shares of Syndax Pharmaceuticals by 104.8% in the fourth quarter. KBC Group NV now owns 6,954 shares of the company’s stock valued at $92,000 after buying an additional 3,559 shares during the last quarter. Stifel Financial Corp purchased a new position in shares of Syndax Pharmaceuticals during the third quarter valued at approximately $327,000. Finally, Quest Partners LLC boosted its position in Syndax Pharmaceuticals by 31.0% during the third quarter. Quest Partners LLC now owns 17,858 shares of the company’s stock worth $344,000 after acquiring an additional 4,223 shares during the last quarter.

Insider Buying and Selling

In related news, CFO Keith A. Goldan sold 3,777 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $58,543.50. Following the sale, the chief financial officer now directly owns 90,746 shares in the company, valued at approximately $1,406,563. This trade represents a 4.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Neil Gallagher sold 4,618 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $71,579.00. Following the transaction, the insider now directly owns 85,095 shares in the company, valued at $1,318,972.50. This trade represents a 5.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 21,683 shares of company stock valued at $336,087. Company insiders own 4.10% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the company. StockNews.com downgraded Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 23rd. Citigroup reduced their target price on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Scotiabank dropped their price objective on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. Finally, JPMorgan Chase & Co. raised their target price on shares of Syndax Pharmaceuticals from $35.00 to $39.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $36.00.

Syndax Pharmaceuticals Stock Performance

Shares of NASDAQ:SNDX opened at $13.04 on Tuesday. The stock has a 50-day simple moving average of $14.26 and a 200-day simple moving average of $16.25. The stock has a market capitalization of $1.12 billion, a P/E ratio of -3.59 and a beta of 0.92. Syndax Pharmaceuticals, Inc. has a 1 year low of $12.06 and a 1 year high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The business had revenue of $7.68 million for the quarter, compared to the consensus estimate of $86.32 million. Analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).